title: [Reduction of central sleep apnea in heart failure patients with beta-blockers therapy].
abstract: BACKGROUND
  Sleep apneas are frequent in patients with heart failure (HF). Estimate of the pre-beta blocker age (BB) point out to 45% of central apneas in these patients.
  
  
  OBJECTIVE
  Assess the influence of BB in central apneas and their interference in the quality of sleep and life of patients with heart failure.
  
  
  METHODS
  65 patients with heart failure underwent diagnostic polysomnography. Polysomnography have been assessed according to the use or not of BB. On the day of examination, the patients answered the Minnesota questionnaire for quality of life with HF. After 6 and 12 months from the polysomnography date, all patients were contacted by phone, in order to repeat the Minnesota questionnaire.
  
  
  RESULTS
  The prevalence of sleep apnea (IAH > 15/h) hit 46.1% in the total population, however, central sleep apnea was identified in 18.4% of patients. The use of BB, in a multivariate analysis, was the only predictor of a minor index of central apnea and hypopnea (IAH) (p=0.002), greater saturation (p=0.02) and smaller average desaturation of oxygen (p=0.03). Additionally, the use of BB could predict a better quality of life after 6 and 12 months (p=0.002 and 0.001 respectively) and a smaller number admissions in these periods (p=0.001 and p=0.05 respectively).
  
  
  CONCLUSIONS
  The use BB reduced the rate of central sleep apnea in total population, if we compare to literature data. Additionally, the BB improved parameters of quality of sleep and life of patients with heart failure.
authors.affiliation: Instituto do Coração, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil. chrispsilva@cardiol.br
authors.forename: Christiano Pereira
authors.initials: CP
authors.lastname: Silva
authors.forename: Geraldo
authors.initials: G
authors.lastname: Lorenzi-Filho
authors.forename: Bianca
authors.initials: B
authors.lastname: Marcondes
authors.forename: Gilmar
authors.initials: G
authors.lastname: Osmundo
authors.forename: Sandrigo
authors.initials: S
authors.lastname: Mangini
authors.forename: Aguinaldo Figueiredo
authors.initials: AF
authors.lastname: Freitas
authors.forename: Phillipe Vieira
authors.initials: PV
authors.lastname: Pires
authors.forename: Edimar Alcides
authors.initials: EA
authors.lastname: Bocchi
authors.forename: Fernando
authors.initials: F
authors.lastname: Bacal
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001938:Brazil / Q000453:epidemiology; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011788:Quality of Life; D020182:Sleep Apnea, Central / Q000453:epidemiology* / Q000473:pathology / Q000517:prevention & control*; D018709:Statistics, Nonparametric
chemical_list: D000319:Adrenergic beta-Antagonists